HGEN was expanded to 515 at 75% point. Their original study only had 300 patients. They underestimated Mayo Clinic’s standard care being so well. Cydy never had 75% review to be told whether they need to expand. Only 50%. So like 120 people. Their drug will not meet end point at all. You have no data of how diversify the study is, which is another RED FLAG. HGEN posted the current demopraphics from race cormobities and etc on presentations. It is perfectly diverse for FDA Approval. Def was guided by Mayo Clinic and OWS. Very good study. And now we know they will 100% meet significance and end point with trial. It’s the safest and easiest gamble you can have.
Market Data 
Markets 
AI
